Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare and highly lethal malignancy, representing 0.02% of all carcinomas. With an incidence of 2.5 cases per million individuals and generating a 5-year survival of less than 25% for advanced cancers, it remains a significant clinical challenge as effective systemic therapy options continue to evade clinicians and scientists [1, 2]. In general, patients present with advanced disease (20%-40% metastatic) owing to limited screening modalities, and the retroperitoneal location of the tumor which facilitates extensive invasion and growth before symptoms arise [3, 4].
26/01/2022